Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.
Stay connected to what’s important in medical research and clinical practice
Subscribe to the most trusted
and influential source of
Already a subscriber? Renew or Sign in
View all specialties
View all topics
View all multimedia
Browse full issue index
Recently Published Articles
Browse recently published
View all learning/CME
Other NEJM Group Learning
This article is available to subscribers. Subscribe now. Already have an account? Sign in
Aducanumab’s price can inform the drug-pricing policy debate because it responds to key features of the market environment for physician-administered drugs: Medicare’s reimbursement formula, payment to physicians for infused drugs, and cost-sharing requirements.
Select an option below:
Are you a member of an institution such as a university or hospital?
Learn more about Institutional Access
Disclosure forms provided by the author are available at NEJM.org.
This article was published on November 20, 2021, at NEJM.org.
From the University of California, Berkeley, School of Public Health, Berkeley.
November 25, 2021
N Engl J Med 2021; 385:2017-2019
Print Subscriber? Activate your online access.
Back to top
Create your account for 2 FREE subscriber-only articles each month.